Appointment sheet
Papillary carcinomas of the breast (encapsulated, solid and invasive papillary)
Prepared with OnCo (onco.cc/prep/papillary-carcinoma-breast/). Orientation, not medical advice; your team knows your case.
My details
Name
Date of appointment
Hospital and clinician
Who is coming with me
What I know, what is unclear, changes to discuss
Saved in this browserWhat I know so far
What is unclear to me
Changes since last time
My questions
9 on the sheetNewly diagnosed
- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Absence of a myoepithelial layer, Oestrogen and progesterone receptor positive, HER2 negative, Ki-67, Neuroendocrine markers in solid papillary carcinoma), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
Encapsulated or solid, no conventional invasion
- 5.For my situation (encapsulated or solid, no conventional invasion), which of the standard options do you recommend and why?
- 6.Am I a candidate for Tamoxifen, and what side effects should I expect?
With conventional invasive carcinoma
- 7.For my situation (with conventional invasive carcinoma), which of the standard options do you recommend and why?
Any stage
- 8.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 9.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Tests and results to bring
Biomarker results to ask for: Absence of a myoepithelial layer (encapsulated and solid forms), Oestrogen and progesterone receptor positive, HER2 negative, Ki-67 (low), Neuroendocrine markers in solid papillary carcinoma.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Encapsulated or solid, no conventional invasion: Managed as ductal carcinoma in situ: excision, with radiotherapy and endocrine therapy considered. (Ductal carcinoma in situ (DCIS), Tamoxifen)
- With conventional invasive carcinoma: Treated as HR-positive breast cancer. (HR-positive / HER2-negative breast cancer, Endocrine therapy (SERMs, AIs, SERDs))
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.
Answers and next steps
Saved in this browserWhat I was told
Agreed next steps, dates and who to call